Status:
COMPLETED
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Appetite and General Nutritional Disorders
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food int...
Detailed Description
Understanding the exact mechanisms by which GLP-1 inhibits eating can be crucial in order to convert its anorectic action into useful, safe and effective drugs. So far, it is however not clear to what...
Eligibility Criteria
Inclusion
- Healthy male subject with a BMI of 19-25 m2/kg
- Stable body weight for at least three months
- Normal eating habits
- Age between 18 and 45 years
- Sufficient understanding of the German language
- Subjects understand the procedures and the risks associated with the study
- Participants must be willing to adhere to the protocol and sign the consent form
Exclusion
- Participation in another clinical trial (currently or within the last 30 days)
- Smoking
- Substance abuse
- Regular intake of medications (except for oral contraceptives)
- Chronic or acute medical condition including clinically relevant abnormality in physical exam or laboratory values
- History of gastrointestinal disorders
- Food allergies
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01900340
Start Date
November 1 2011
End Date
December 1 2012
Last Update
July 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Phase 1 Research Unit
Basel, Switzerland